Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2025)

Sutro Biopharma's Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $10.6 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 84.86% year-over-year to $10.6 million; the TTM figure through Dec 2025 stood at $10.6 million (down 84.86% YoY), while the FY2025 annual figure was $10.6 million, down 84.86% from the prior year.
• Current Deferred Revenue came in at $10.6 million for Q4 2025 at Sutro Biopharma, up from $9.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $74.0 million in Q2 2024 to a low of $5.5 million in Q4 2021.
• A 5-year average of $24.8 million and a median of $16.3 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 310.09% in 2024 and tumbled 87.63% in 2025, its largest moves.
• Sutro Biopharma's Current Deferred Revenue stood at $5.5 million in 2021, then jumped by 204.93% to $16.8 million in 2022, then grew by 23.31% to $20.7 million in 2023, then jumped by 237.67% to $69.8 million in 2024, then slumped by 84.86% to $10.6 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $10.6 million, $9.0 million, and $12.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison